ReviewAnnals of translational medicine2018
The emerging treatment landscape of advanced non-small cell lung cancer.
Review in Annals of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Toward development of soil-derivedBiodesign research · 2026Article
- Vitiligo-like rash in a patient with lung cancer caused by sintilimab: A case report.World journal of clinical cases · 2025Article
- Non-Viral RNA Therapies for Non-Small Cell Lung Cancer and Their Corresponding Clinical Trials.Molecular pharmaceutics · 2025Review
- Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study.Therapeutic advances in medical oncology · 2025Article
- Fatty acid metabolism prognostic signature predicts tumor immune microenvironment and immunotherapy, and identifies tumorigenic role of MOGAT2 in lung adenocarcinoma.Frontiers in immunology · 2024Article
- EGFR TKI resistance in lung cancer cells using RNA sequencing and analytical bioinformatics tools.Journal of biomolecular structure & dynamics · 2023Article
- 2-methoxyestradiol restrains non-small cell lung cancer tumorigenesis through regulating circ_0010235/miR-34a-5p/NFAT5 axis.Thoracic cancer · 2023Article
- The Small RNA Landscape in NSCLC: Current Therapeutic Applications and Progresses.International journal of molecular sciences · 2023Review
- Favorable Conditions for the Detection of EGFR T790M Mutation Using Plasma Sample in Patients with Non-Small-Cell Lung Cancer.Cancers · 2023Article
- Harnessing chlorin e6 loaded by functionalized iron oxide nanoparticles linked with glucose for target photodynamic therapy and improving of the immunogenicity of lung cancer.Journal of cancer research and clinical oncology · 2022Article
- Real-world evaluation of molecular testing and treatment patterns for EGFR mutations in non-small cell lung cancer in Latin America.Molecular and clinical oncology · 2022Article
- Chlorin e6-Induced Photodynamic Effect Polarizes the Macrophage Into an M1 Phenotype Through Oxidative DNA Damage and Activation of STING.Frontiers in pharmacology · 2022Article
- Risk Factors for Thyroid Dysfunction in Patients with Advanced Non-Small-Cell Lung Cancer Treated with PD-1 Antibody.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- The prognostic value of 4.1 mRNA expression in non-small cell lung cancer.Translational cancer research · 2021Article
- Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.Journal of managed care & specialty pharmacy · 2020Article
- Actin-like protein 8 promotes cell proliferation, colony-formation, proangiogenesis, migration and invasion in lung adenocarcinoma cells.Thoracic cancer · 2020Article
- MIER3 suppresses the progression of non-small cell lung cancer by inhibiting Wnt/β-Catenin pathway and histone acetyltransferase activity.Translational cancer research · 2020Article
- Axl-Targeted Delivery of the Oncosuppressor miR-137 in Non-small-Cell Lung Cancer.Molecular therapy. Nucleic acids · 2019Article
- Reliability of PD-L1 assays using small tissue samples compared with surgical specimens.Medicine · 2019Observational
- miR‑505 inhibits cell growth and EMT by targeting MAP3K3 through the AKT‑NFκB pathway in NSCLC cells.International journal of molecular medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains the leading cause of cancer related death worldwide. Despite broad advances in diagnostics and therapy, the five-year overall survival for patients with advanced non-small cell lung cancer (NSCLC) has not significantly changed over the past few years. Following the decoding of human cancer genome and the advent of therapies targeting driver mutations, the selection of systemic therapy changed from "one size fits all" approach to a more precise selection of biologic therapies targeting distinct genetic profiles. Molecular alterations can be targeted by specific drugs that are administered orally, have higher response rates and a better toxicity profile compared to standard chemotherapy. More recently, better understanding of the interactions between tumor cells and the immune system has led to the development of new therapeutic strategies that enhance the body's own immune response towards antitumor immunity. Robust data on these new drugs have been generated not only in the second-line setting, but also as first line therapy and in combination with standard therapies. In this review, we aim to illustrate a comprehensive up-to-date within the newest advances in the field of NSCLC, with the view to educate new practitioners and stimulate new thoughts for clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.